Literature DB >> 33936378

Castleman's disease of the left parotid gland: a case report.

Zhenfei Guo1, Chang Liu1, Jing Sun2, Linggong Zeng3, Kai Zhang1.   

Abstract

Castleman's disease is a very rare heterogeneous group of lymphoproliferative disorders characterized by non-neoplastic growths. It is unknown about the pathophysiology of the Castleman's disease. Previous studies demonstrated that Castleman's disease can be divided into two groups according to clinical classification, including unicentric Castleman disease (UCD) and multicentric Castleman disease (MCD). The hyaline vascular type is most common in the head and neck, and is abbreviated as UCD. In the present case, a woman complained that a mass in her parotid gland was growing and it was painless seven months ago. The computed tomography (CT) showed that the superficial lobe of the parotid gland on the left had an elliptical soft tissue density shadow, about 2.5×3.5 cm, with clear boundaries and no obvious abnormalities in the surrounding bone. The CT scan showed no obvious abnormalities in the shape and density of the right parotid and bilateral submandibular glands. After the operation, combined with the results of immunohistochemistry, the final diagnosis was Castleman tumor. The patient recovered smoothly, after the operation and during follow-up. The patient maintained good health without recurrence or metastasis. IJCEP
Copyright © 2021.

Entities:  

Keywords:  Castleman disease; hyaline vascular type; parotid gland; unicentric Castleman disease

Year:  2021        PMID: 33936378      PMCID: PMC8085830     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

1.  Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway.

Authors:  Jean-Benoît Arlet; Olivier Hermine; Luc Darnige; Vaughn Ostland; Mark Westerman; Cécile Badoual; Jacques Pouchot; Loïc Capron
Journal:  Pediatrics       Date:  2010-11-01       Impact factor: 7.124

2.  Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer.

Authors:  Mari Ohtaka; Takashi Kawahara; Yukari Ishiguro; Meenal Sharma; Masahiro Yao; Hiroshi Miyamoto; Hiroji Uemura
Journal:  Int J Urol       Date:  2018-07-24       Impact factor: 3.369

3.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

4.  Report of a case of localized Castleman's disease with progression to malignant lymphoma.

Authors:  V Franco
Journal:  Am J Clin Pathol       Date:  1993-12       Impact factor: 2.493

5.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients.

Authors:  G Frizzera; P M Banks; G Massarelli; J Rosai
Journal:  Am J Surg Pathol       Date:  1983-04       Impact factor: 6.394

Review 6.  Castleman Disease.

Authors:  Wei Wang; L Jeffrey Medeiros
Journal:  Surg Pathol Clin       Date:  2019-05-23

7.  Surgical management of abdominal and retroperitoneal Castleman's disease.

Authors:  Pascal Bucher; Gilles Chassot; Guillaume Zufferey; Frederic Ris; Olivier Huber; Philippe Morel
Journal:  World J Surg Oncol       Date:  2005-06-07       Impact factor: 2.754

8.  Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases.

Authors:  David Boutboul; Jehane Fadlallah; Sylvain Chawki; Claire Fieschi; Marion Malphettes; Antoine Dossier; Laurence Gérard; Pierre Mordant; Véronique Meignin; Eric Oksenhendler; Lionel Galicier
Journal:  Br J Haematol       Date:  2019-04-23       Impact factor: 6.998

9.  Castleman's disease combined with choledocholithiasis: a case report and review of literature.

Authors:  Zhi-Jia Jiang; Shuang Feng; Geng Liu; Ming Chen; Jin-Jin Sun
Journal:  Int J Clin Exp Pathol       Date:  2018-11-01

Review 10.  Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review.

Authors:  Małgorzata Wojtyś; Agnieszka Piekarska; Michał Kunc; Konrad Ptaszyński; Wojciech Biernat; Jan Maciej Zaucha; Piotr Waloszczyk; Piotr Lisowski; Bartosz Kubisa; Tomasz Grodzki
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

View more
  2 in total

1.  Comprehensive analysis of 65 patients with Castleman disease in a single center in China.

Authors:  Xi-Qian Wang; Nian-Nian Zhong; Qi Sun; Si-Chen Yan; Guang-Cai Xu; Yong-Gong Wang; Li-Wei Peng; Bing Liu; Lin-Lin Bu
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

2.  Case Report: A rare case of primary hepatic Castleman's disease mimicking a liver tumor.

Authors:  Hong Chen; Xiaoxi Pang; Jie Li; Baixuan Xu; Yachao Liu
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.